Risk of Adverse Cardiovascular Events Following a Myocardial Infarction in Patients Receiving Combined Clopidogrel...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• The interaction between proton pump inhibitors (PPIs) and clopidogrel has been a long-standing clinical concern.
• Previous studies have yielded conflicting results regarding the safety of this drug combination.

Purpose of the Study:

• To investigate the association between combined clopidogrel and PPI treatment and the risk of recurrent myocardial infarction (MI).
• To evaluate secondary outcomes related to this drug interaction.

Main Methods:

• A nested case-control study utilized the Cerner Health Facts® database.
• A retrospective cohort of 52,006 patients experiencing a first MI and initiating clopidogrel was analyzed.
• Logistic regression models were employed to calculate adjusted odds ratios (aORs), with comparisons made against negative control drugs.

Main Results:

• No significant association was found between clopidogrel/PPI use and recurrent MI in the overall cohort (aOR 1.08; 95% CI 0.95-1.23).
• A potential increased risk of MI was observed in patients aged 80-89 years (aOR 1.26; 95% CI 1.05-1.51).
• No significant associations were observed with H2 receptor antagonists or with PPIs in patients taking prasugrel or ticagrelor.

Conclusions:

• The study's findings do not support a significant adverse clinical impact of concomitant clopidogrel and PPI use in MI patients.
• Further investigation into the observed association in the 80-89 year age group is warranted.